# EDGAR Filing Document

**Accession Number:** 0001622229
**File Stem:** 0001193125-26-054555
**Filing Date:** 2026-2
**Character Count:** 25184
**Document Hash:** c7c821dfa4774b5c9c6c7318ecb81d97
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-054555.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001193125-26-054555

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**EFFECTIVENESS DATE**: 20260217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cogent Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001622229
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 465308248
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293512
- **FILM NUMBER:** 26640773

**BUSINESS ADDRESS:**
- **STREET 1:** 275 WYMAN STREET
- **STREET 2:** 3RD FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 617-945-5576

**MAIL ADDRESS:**
- **STREET 1:** 275 WYMAN STREET
- **STREET 2:** 3RD FLOOR
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Unum Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20180402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Unum Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20141014

**As filed with the Securities and Exchange Commission on February 17, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## COGENT BIOSCIENCES, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **46-5308248** |
| **(State or Other Jurisdiction<br>of Incorporation or Organization)** | **(I.R.S. Employer<br>Identification No.)** |

---

**275 Wyman Street, 3rd Floor** 

**Waltham, Massachusetts 02451** 

**(Address of Principal Executive Offices, Zip Code)** 

**Amended and Restated Cogent Biosciences, Inc. 2018 Stock Option and Incentive Plan** 

**Cogent Biosciences, Inc. 2018 Employee Stock Purchase Plan** 

**Cogent Biosciences, Inc. 2020 Inducement Plan** 

**(Full title of the plans)** 

**Andrew Robbins** 

**President and Chief Executive Officer** 

**275 Wyman Street, 3rd Floor** 

**Waltham, Massachusetts 02451** 

**(Name and address of agent for service)** 

**(617) 945-5576** 

**(Telephone number, including area code, of agent for service)** 

***Copies to*:** 

**Sean C. Feller** 

**Gibson, Dunn & Crutcher LLP** 

**2000 Avenue of the Stars, Suite 1200N** 

**Los Angeles, CA 90067** 

**(310) 552-8500** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☑ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**INTRODUCTION** 

This Registration Statement on Form S-8 is filed by Cogent Biosciences, Inc. (the "Registrant") to register an additional (i) 6,439,201 shares of its common stock, par value $0.001 per share ("Common Stock"), available for issuance pursuant to the Amended and Restated Cogent Biosciences, Inc. 2018 Stock Option and Incentive Plan, (ii) 125,000 shares of Common Stock available for issuance pursuant to the Cogent Biosciences, Inc. 2018 Employee Stock Purchase Plan, and (iii) 1,500,000 shares of Common Stock available for issuance pursuant to the Cogent Biosciences, Inc. 2020 Inducement Plan.

Pursuant to General Instruction E of Form S-8, the information contained in the Registrant's Registration Statements on Form S-8 filed on [February 25, 2025](http://www.sec.gov/Archives/edgar/data/1622229/000119312525035115/d923574ds8.htm) (Registration No. 333-285198), [February 26, 2024](http://www.sec.gov/Archives/edgar/data/1622229/000119312524046239/d775409ds8.htm) (Registration No. 333-277360), [August 8, 2023](http://www.sec.gov/Archives/edgar/data/1622229/000119312523206264/d531544ds8.htm) (Registration No. 333-273802), [March 14, 2023](http://www.sec.gov/Archives/edgar/data/1622229/000119312523070121/d439503ds8.htm) (Registration No. 333-270522), [March 17, 2022](http://www.sec.gov/Archives/edgar/data/1622229/000119312522078297/d280470ds8.htm) (Registration No. 333-263638), [August 17, 2021](http://www.sec.gov/Archives/edgar/data/1622229/000119312521248036/d218498ds8.htm) (Registration No. 333-258865), [March 16, 2021](http://www.sec.gov/Archives/edgar/data/1622229/000119312521082174/d227846ds8.htm) (Registration No. 333-254320), [November 5, 2020](http://www.sec.gov/Archives/edgar/data/1622229/000119312520286975/d74918ds8.htm) (Registration No. 333-249884), [March 26, 2020](http://www.sec.gov/Archives/edgar/data/1622229/000119312520086958/d885183ds8.htm) (Registration No. 333-237406), [March 28, 2019](http://www.sec.gov/Archives/edgar/data/1622229/000119312519089341/d658450ds8.htm) (Registration No. 333-230559) and [April 4, 2018](http://www.sec.gov/Archives/edgar/data/1622229/000119312518107577/d687916ds8.htm) (Registration No. 333-224137), together with all exhibits filed therewith or incorporated therein by reference, is hereby incorporated by reference and made a part hereof, except for those items being updated by this Registration Statement.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 6.** **Indemnification of Directors and Officers.** <br>

Section 145 of the Delaware General Corporation Law, or the DGCL, authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys' fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys' fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

The Registrant has adopted provisions in its certificate of incorporation that limit or eliminate the personal liability of its directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any breach of the director's duty of loyalty to the Registrant or its stockholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any transaction from which the director derived an improper personal benefit.

The Registrant has also adopted provisions in its certificate of incorporation that limit or eliminate the personal liability of its officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, an officer will not be personally liable to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as an officer, except for liability for:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• breach of fiduciary duty claims brought by the Registrant itself;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• derivative claims brought by stockholders in the name of the Registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any breach of the officer's duty of loyalty to the Registrant or its stockholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• any transaction from which the officer derived an improper personal benefit.

These limitations of liability do not alter director and officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

In addition, the Registrant's bylaws provide that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• it will indemnify its directors, officers and, in the discretion of the Registrant's board of directors,
certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• it will advance reasonable expenses, including attorneys' fees, to its directors and, in the discretion of
the Registrant's board of directors, to its officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of the Registrant, subject to limited exceptions.

The Registrant has entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the Registrant will indemnify each of its directors and executive officers to the fullest extent permitted by Delaware law.

The Registrant also maintains general liability insurance which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended (the "Securities Act").

**Item 8.** **Exhibits.** <br>

---

| | |
|:---|:---|
| Exhibit No. | Exhibit Description |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Fourth Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed on June 5, 2025).](http://www.sec.gov/Archives/edgar/data/1622229/000119312525135337/d20143dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed on October 5, 2020).](http://www.sec.gov/Archives/edgar/data/1622229/000119312520263412/d14737dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Gibson, Dunn & Crutcher LLP (filed herewith).](d39919dex51.htm) |
| 23.1 | [Consent of PricewaterhouseCoopers LLP (filed herewith), independent registered public accounting firm.](d39919dex231.htm) |
| 23.2 | [Consent of Gibson, Dunn & Crutcher LLP (incorporated by reference from Exhibit 5.1).](d39919dex51.htm) |
| 24.1 | [Power of Attorney (included on the signature pages hereof).](d39919ds8.htm#sig) |
| 99.1 | [Amended and Restated Cogent Biosciences, Inc. 2018 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant's Annual Report on Form 10-K filed on February 17, 2026).](http://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-ex10_2.htm) |
| 99.2 | [Cogent Biosciences, Inc. 2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to the Registrant's Annual Report on Form 10-K filed on March 16, 2021).](http://www.sec.gov/Archives/edgar/data/1622229/000156459021013325/cogt-ex105_109.htm) |
| 99.3 | [Cogent Biosciences, Inc. 2020 Inducement Plan (incorporated by reference to Exhibit 10.3 to the Registrant's Annual Report on Form 10-K filed on February 17, 2026).](http://www.sec.gov/Archives/edgar/data/1622229/000119312526053334/cogt-ex10_3.htm) |
| 107.1 | [Filing Fee Table (filed herewith).](d39919dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on February 17, 2026.

---

| | |
|:---|:---|
|  **COGENT BIOSCIENCES, INC.** | **COGENT BIOSCIENCES, INC.** |
|  By: | /s/ Andrew Robbins |
|  Name: | Andrew Robbins |
|  Title: | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Andrew Robbins, John Green, and Evan Kearns, and each of them severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, in connection with this Registration Statement, including to sign and file in the name and on behalf of the undersigned as a director or officer of Cogent Biosciences, Inc. (1) any and all amendments or supplements (including any and all stickers and post-effective amendments) to this Registration Statement, with all exhibits thereto, and other documents in connection therewith, and (2) any and all additional registration statements, and any and all amendments thereto, relating to the same offering of securities as those that are covered by this Registration Statement that are filed pursuant to Rule 462(b) promulgated under the Securities Act with the Securities and Exchange Commission and any applicable securities exchange or securities self-regulatory body, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, the following persons have signed this Registration Statement in the capacities and on the date(s) indicated.

------

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| /s/ Andrew Robbins <br>Andrew Robbins | President, Chief Executive<br> Officer and Director<br> (*Principal Executive Officer*) | February 17, 2026 |
| /s/ John Green <br>John Green | Chief Financial Officer<br> (*Principal Financial Officer*<br> *and Principal Accounting*<br> *Officer*) | February 17, 2026 |
| /s/ Chris Cain, Ph.D. <br>Chris Cain, Ph.D. | Director | February 17, 2026 |
| /s/ Karen Ferrante, M.D. <br>Karen Ferrante, M.D. | Director | February 17, 2026 |
| /s/ Peter Harwin <br>Peter Harwin | Director | February 17, 2026 |
| /s/ Arlene M. Morris <br>Arlene M. Morris | Director | February 17, 2026 |
| /s/ Matthew E. Ros <br>Matthew E. Ros | Director | February 17, 2026 |
| /s/ Todd E. Shegog <br>Todd E. Shegog | Director | February 17, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g39919g73d86.jpg)

February 17, 2026

Cogent Biosciences, Inc.

275 Wyman Street, 3rd Floor

Waltham, Massachusetts 02451

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "Registration Statement") of Cogent Biosciences, Inc., a Delaware corporation (the "Company"), to be filed with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), in connection with the offering by the Company of up to 8,064,201 shares of the Company's common stock, par value $0.001 per share (the "Shares"). The Shares are to be issued under the Amended and Restated Cogent Biosciences, Inc. 2018 Stock Option and Incentive Plan, the Cogent Biosciences, Inc. 2018 Employee Stock Purchase Plan, and the Cogent Biosciences, Inc. 2020 Inducement Plan (collectively, the "Plans").

In arriving at the opinions expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of such documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinions set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies.

We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plans that would expand, modify or otherwise affect the terms of the Plans or the respective rights or obligations of the participants thereunder. Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued and sold against payment therefor as set forth in the Plans, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "DGCL"). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

---

| |
|:---|
|  Very truly yours, |
|  /s/ Gibson, Dunn & Crutcher LLP |

---

**Gibson, Dunn & Crutcher LLP**

2000 Avenue of the Stars Suite 1200N \| Los Angeles, CA 90067-4700 \| T: 310.552.8500 \| F: 310.551.8741 \| gibsondunn.com

## Exhibit 23.1

**Exhibit 23.1** 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Cogent Biosciences, Inc. of our report dated February 17, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Cogent Biosciences, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

February 17, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Cogent Biosciences, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, par value $0.001 per share (the "Common Stock"), to be issued pursuant to the Amended and Restated Cogent Biosciences, Inc. 2018 Stock Option and Incentive Plan (the "2018 Plan") | 457(a) | 6439201 | $36.93 | $237799692.93 | 0.0001381 | $32840.14 |
| 2 | Equity | Common Stock to be issued pursuant to the Cogent Biosciences, Inc. 2018 Employee Stock Purchase Plan (the "ESPP") | 457(a) | 125000 | $31.39 | $3923750.00 | 0.0001381 | $541.87 |
| 3 | Equity | Common Stock to be issued pursuant to the Cogent Biosciences, Inc. 2020 Inducement Plan (the "Inducement Plan") | 457(a) | 1500000 | $36.93 | $55395000.00 | 0.0001381 | $7650.05 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $297118442.93  |  | $41032.06  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $41032.06  |

---

 **Offering Note** <br>

<sup>1</sup> In addition to the number of shares of the Common Stock of the Registrant stated above, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers any additional shares of Common Stock that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. The amount registered represents an automatic increase to the number of shares available for issuance under the 2018 Plan in accordance with the automatic annual increase provision therein, effective as of January 1, 2026. The price of $36.93 per share, which is the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Global Select Market on February 11, 2026, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act and has been used as these shares are without a fixed price

<sup>2</sup> In addition to the number of shares of the Common Stock of the Registrant stated above, pursuant to Rule 416 under the Securities Act, this Registration Statement also covers any additional shares of Common Stock that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. The amount registered represents an automatic increase to the number of shares available for issuance under the ESPP in accordance with the automatic annual increase provision therein, effective as of January 1, 2026. The price of $31.39 per share is estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act, and is based on 85% of $36.93, which is the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Global Select Market on February 11, 2026. Pursuant to the ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the fair market value of a share of Common Stock on the first trading day of the offering period or on the exercise date, whichever is less.

<sup>3</sup> In addition to the number of shares of the Common Stock of the Registrant stated above, pursuant to Rule 416 under the Securities Act, this Registration Statement also covers any additional shares of Common Stock that become issuable by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding shares of Common Stock. The amount registered represents additional shares added to the Inducement Plan. The price of $36.93 per share, which is the average of the high and low sale prices of the Common Stock of the Registrant as quoted on the Nasdaq Global Select Market on February 11, 2026, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act and has been used as these shares are without a fixed price.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---